Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• Myeloproliferative Neoplasms (MPNs) are often driven by mutations affecting cell signaling.
• The Janus kinase-signal transducers and activators of transcription (JAK-STAT) and phosphotidylinositide-3 kinase (PI3K) pathways are crucial for cell survival and apoptosis.
• The JAK2 V617F mutation is the most common genetic alteration in MPNs, leading to constitutive pathway activation.

Purpose of the Study:

• To investigate the association between specific MPN mutations and the phosphorylation status of STAT5 and Akt.
• To evaluate the utility of immunocytochemistry for phospho-proteins as a diagnostic tool in MPNs.

Main Methods:

• Monoclonal antibodies against phospho-STAT5 and phospho-Akt were developed.
• Immunocytochemistry was performed on bone marrow biopsies from MPN patients with JAK2 V617F, JAK2 exon 12, MPL exon 10, and KIT D816V mutations.

Main Results:

• JAK2 V617F mutation significantly increased phospho-STAT5 and phospho-Akt levels in hematopoietic cells, especially megakaryocytes.
• JAK2 exon 12 and MPL exon 10 mutations did not alter phosphorylation levels.
• KIT D816V mutation in systemic mastocytosis showed increased phospho-STAT5 and phospho-Akt in neoplastic mast cells, but not other hematopoietic cells.

Conclusions:

• JAK2 V617F is linked to upregulated STAT5 and Akt phosphorylation in megakaryocytes and other hematopoietic cells.
• Immunocytochemistry for phospho-proteins in bone marrow trephines can serve as a supplementary diagnostic test for MPNs.
• This method demonstrates a high negative predictive value for diagnosing MPNs associated with specific mutations.